CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 10 enrolled
Drug / intervention
Maravirocdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02881762
NCT02881762Phase 4Completed
CompareCT.gov

A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C

University of Maryland, Baltimore·interventional·Posted Aug 29, 2016·Updated May 1, 2024

In Brief

A Phase 4 clinical trial evaluating Maraviroc for Hepatitis C and Human Immunodeficiency Virus. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This is a single-site, longitudinal, open-label, interventional study for evaluating the effect of maraviroc on hepatitis C viral levels in patients infected with both hepatitis C and human immunodeficiency virus (HIV) and taking antiretroviral therapy for HIV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Human Immunodeficiency Virus
CountriesUnited States
CollaboratorsViiV Healthcare

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 29, 2016
Enrollment StartJun 1, 2017
Primary CompletionMar 27, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.8 years ago

Interventions

Maravirocdrug

Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.